Genentech Presents Two-Year Data of Vabysmo in P-III (TENAYA) and (LUCERNE) Studies for Wet Age-Related Macular Degeneration at ASRS 2022
Shots:
- The P-III (TENAYA) & (LUCERNE) studies evaluating Vabysmo vs aflibercept in 1329 patients with wet AMD
- The results showed that 59% & 67% of Vabysmo patients achieved 4mos. in (TENAYA) & (LUCERNE) studies @2yrs.; improvement above 1yr. outcomes (45% & 46%)., 80% could be treated q3mos. or longer at the end of 2yr., patients received a median number of 10 inj. vs 15 inj. @2yrs., reductions in CST in patients with Vabysmo given at ~4mos. vs aflibercept at q2mos. with no new safety signals, was well tolerated with a favorable benefit-risk profile
- Improvements in vision across both treatment arms. The safety results were consistent with no reported cases of retinal vasculitis or IOI associated with retinal vein or retinal artery occlusion
Ref: Bussinesswire | Image: Genentech
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
